Diabetes is a common metabolic disease having serious health implications and its incidence is increasing day by day. The global burden of diabetes is alarmingly high, with over 382 million diabetics in 2013 which is expected to rise up to 592 million by 2035 [1]. 60% of the world diabetic population resides in Asia [1], with Southeast Asia having around 72 million adults with diabetes in 2013 and this figure is expected to rise to 123 million by 2035 [2]. Long-term diabetes presents with various complications including retinopathy, nephropathy, neuropathy, arteriosclerosis etc. One of the many complications of diabetes mellitus is diabetic peripheral neuropathy (DPN), which is defined as “the presence of symptoms or signs of peripheral nerve dysfunction in people with diabetes after exclusion of other causes [3]. It is estimated that 60% to 70% of diabetics have mild to severe forms of nervous system damage [4]. DPN is one of the serious known micro vascular complications of both type 1 and type 2 diabetes mellitus having been diagnosed in 20-50% of the diabetic population.